Literature DB >> 9598911

Prolonged response of multicentric reticulohistiocytosis to low dose methotrexate.

J L Rentsch1, E M Martin, L C Harrison, I P Wicks.   

Abstract

We describe a case of multicentric reticulohistiocytosis complicated by central retinal vein thrombosis and trigeminal neuropathy. A variety of treatment modalities were tried in this patient. Both skin disease and arthritis responded to low dose methotrexate over 8 years of followup. Graduated compression gloves produced an excellent cosmetic improvement in the disfiguring skin lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9598911

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Multicentric reticulohistiocytosis: a rare yet challenging disease.

Authors:  Arshia D Islam; Stanley M Naguwa; Gurtej S Cheema; John C Hunter; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 2.  Multicentric reticulohistiocytosis: case report with response to infliximab and review of treatment options.

Authors:  Cristina C Macía-Villa; Antonio Zea-Mendoza
Journal:  Clin Rheumatol       Date:  2014-04-15       Impact factor: 2.980

3.  Malignancy-associated multicentric reticulohistiocytosis.

Authors:  Boutros El-Haddad; Dalia Hammoud; Timothy Shaver; Shadi Shahouri
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

4.  Multicentric reticulohistiocytosis with prominent skin lesions and arthritis: A case report.

Authors:  Xiao-Li Xu; Xiao-Hong Liang; Juan Liu; Xu Deng; Lu Zhang; Zhi-Gang Wang
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

5.  Case Report: Multicentric Reticulohistiocytosis Associated With Posterior Mediastinal Adenosquamous Carcinoma, Antinuclear Antibody Positivity and Lupus Anticoagulant Positivity.

Authors:  Ziyi Tang; Xiangpeng Wang; Zijing Xia; Zhongming Wang; Yi Zhao; Yi Liu
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.